The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular…
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular…
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular…
ST. LOUIS, May 15, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…
Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half…
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesLOS ANGELES, May 09, 2024 (GLOBE…
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and CompaniesLOS ANGELES, May 09, 2024 (GLOBE…
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting…
BOSTON--(BUSINESS WIRE)--Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Peter F.…